Erasca Inc. Prices Upsized Public Offering of $225 Million in Common Stock
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 22 2026
0mins
Source: Newsfilter
- Offering Size: Erasca Inc. announced a public offering of 22.5 million shares at $10.00 per share, expected to raise $225 million, reflecting strong market confidence in its RAS/MAPK pathway cancer therapies.
- Underwriter Selection: J.P. Morgan, Morgan Stanley, Jefferies, and Evercore ISI are acting as joint book-running managers for the offering, indicating their strong influence and expertise in capital markets.
- Use of Proceeds: Erasca intends to utilize the net proceeds from this offering to fund research and development of its product candidates and other development programs, aiming to accelerate innovation in precision oncology and enhance market competitiveness.
- Closing Timeline: The offering is expected to close on January 23, 2026, subject to customary closing conditions, demonstrating the company's efficiency in capital operations and adaptability to market conditions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ERAS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ERAS
Wall Street analysts forecast ERAS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ERAS is 5.50 USD with a low forecast of 2.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
6 Buy
1 Hold
1 Sell
Moderate Buy
Current: 10.310
Low
2.00
Averages
5.50
High
11.00
Current: 10.310
Low
2.00
Averages
5.50
High
11.00
About ERAS
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Erasca Stock Declines Without News Justification
- Stock Decline: Erasca Inc. (NASDAQ:ERAS) shares fell 7.13% to $9.25 on Monday, despite no news justifying the decline, indicating market concerns about its future performance.
- 52-Week Range: The stock is trading near the upper end of its 52-week range of $1.01 to $10.67, reflecting investor apprehension regarding its volatility and potential risks, which could impact its fundraising capabilities and market confidence.
- Acquisition Talks End: Merck & Co. (NYSE:MRK) reportedly ended discussions to acquire Revolution Medicines (NASDAQ:RVMD) due to valuation disagreements, raising concerns about future M&A activities in the oncology sector.
- Funding Plans: Last week, Erasca priced an upsized public offering of 22.5 million shares at $10.00 each, aiming to raise $225 million to fund R&D and other corporate purposes, although the current stock decline may affect its financing outlook.
Continue Reading
Intuitive Surgical (ISRG) Reports Q4 Revenue of $2.87 Billion, Exceeding Expectations
- Earnings Beat: Intuitive Surgical reported Q4 revenue of approximately $2.87 billion and adjusted earnings of $2.53 per share, both exceeding analyst expectations, driven by year-over-year growth in procedure volume and robotic system placements, leading to a rise in after-hours trading.
- Dividend Increase: Kinder Morgan topped Q4 revenue expectations with about $4.51 billion and adjusted earnings of $0.39 per share, while announcing a 2% quarterly dividend increase to $0.2925 per share, despite slightly lowering its 2026 earnings outlook, reflecting cautious sentiment amid ongoing energy market dynamics.
- Expansion Plans: USA Rare Earth announced plans to establish a high-capacity metal and alloy production plant in Lacq, France, capable of producing about 3,750 metric tons per year through its subsidiary Less Common Metals, aimed at strengthening transatlantic supply chains and boosting investor optimism.
- Market Volatility: Despite subdued overall market performance, small-cap benchmarks reached new highs, indicating sustained investor demand for risk assets against a backdrop of easing geopolitical tensions, which positively influenced the performance of certain tech stocks.
Continue Reading